Viral and nonviral uses of imiquimod: A review

Journal of Cutaneous Medicine and Surgery

Volumn 8, Issue 5, 2004, Pages 338-352

  Gupta, Aditya K ^a,b,d   Cherman, Andrea M ^b   Tyring, Stephen K ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b MEDIPROBE RESEARCH INC   (Canada)

^c University of Texas Health Science Center at Houston   (United States)

^d NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; IMIQUIMOD; INTERLEUKIN 12; MEGLUMINE ANTIMONATE; TOLL LIKE RECEPTOR 7; TUMOR NECROSIS FACTOR ALPHA;

ACTINIC KERATOSIS; BASAL CELL CARCINOMA; BOWEN DISEASE; BOWENOID PAPULOSIS; CHEILITIS; CLINICAL TRIAL; CONDYLOMA; CUTANEOUS T CELL LYMPHOMA; DRUG APPROVAL; DRUG MECHANISM; DRUG SAFETY; DRUG USE; DRY SKIN; ERYTHEMA; FIBROSIS; FLU LIKE SYNDROME; GRANULOMA ANNULARE; HERPES SIMPLEX; HUMAN; IMMUNOMODULATION; KELOID; KERATOSIS; MALIGNANT LENTIGO; MEDICAL LITERATURE; MELANOMA; METASTASIS; MOLLUSCUM CONTAGIOSUM; MORPHEA; NAUSEA; NONHUMAN; PAGET SKIN DISEASE; PAIN; PEMPHIGUS; POROKERATOSIS MIBELLI; PRIORITY JOURNAL; PRURITUS; REVIEW; SIDE EFFECT; SKIN BURNING SENSATION; SKIN EDEMA; SKIN HEMANGIOMA; SKIN INDURATION; SKIN IRRITATION; SKIN LEISHMANIASIS; SKIN MANIFESTATION; TATTOO; VERRUCA VULGARIS; VULVA TUMOR; WART VIRUS; XEROSIS;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, TOPICAL; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; BOWEN'S DISEASE; CARCINOMA, BASAL CELL; CLINICAL TRIALS, PHASE III; CONDYLOMATA ACUMINATA; HUMANS; HUTCHINSON'S MELANOTIC FRECKLE; KERATOSIS; MODELS, IMMUNOLOGICAL; OINTMENTS; PAGET'S DISEASE, EXTRAMAMMARY; RANDOMIZED CONTROLLED TRIALS; SKIN DISEASES; SKIN NEOPLASMS;

EID: 27544470370     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10227-005-0023-5     Document Type: Review

References (112)

1. Anonymous Physicians Desk Reference Montvale. Medical Economics, Inc., NJ 2003, pp 1882-1883.
2. 3M Pharmaceuticals. Aldara™ (imiquimod) cream, 5% (package insert), 2004.
3. Slade HB. Cytokine induction and modifying the immune response to human papilloma virus with imiquimod. Eur J Dermatol 1998; 8:13-16.
4. Slade H, Owens M, Tomai M, et al. Imiquimod 5% cream (Aldara™). Exp Opin Invest Drugs 1998; 7:437-449.
5. Miller RL, Gerster JF, Owens ML, et al. Imiquimod applied topically: a novel immune response modifier and new class of drug. Int J Immunopharmacol 1999; 21:1-14.
6. Sauder DN. Immunomodulatory and pharmacologic properties of imiquimod. J Am Acad Dermatol 2000; 43:S6-11.
7. Marini M. Imiquimod 5% cream: a topical immune response modifier. Int J Dermatol 2002; 41 (Suppl 1):1-2.
8. Garland SM. Imiquimod. Curr Opin Infect Dis 2003; 16:85-89.
9. Rigel D, Berman B. Introduction: immunotherapy for dermatologic conditions. Acta Derm Venereol Suppl (Stockh) 2003; Sep (214):5-7.
10. Stanley MA. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin Exp Dermatol 2002; .:571-577.
11. Hurwitz DJ, Pincus L, Kupper TS. Imiquimod: a topically applied link between innate and acquired immunity. Arch Dermatol 2003; 139:1347-1350.
12. Hemmi H, Kaisho T, Takeuchi O, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002; 3:196-200.
13. Tomai MA, Imbertson LM, Stanczak TL, et al. The immune response modifiers imiquimod and R-848 are potent activators of B lymphocytes. Cell Immunol 2000; 203:55-65.
14. Sauder DN. Imiquimod: modes of action. Br J Dermatol 2003; 149 (Suppl 66):5-8.
15. Imbertson LM, Beaurline JM, Couture AM, et al. Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463. J Invest Dermatol 1998; 110:734-739.
16. Syed TA. A review of the applications of imiquimod: a novel immune response modifier. Expert Opin Pharmacother 2001; 2:877-882.
17. Miller R. Imiquimod stimulates innate and cell mediated immunity which controls virus infections and tumors. Int J Dermatol 2002; 41(Suppl 1):3-6.
18. Miller RL, Tomai MA, Harrison CJ, et al. Immunomodulation as a treatment strategy for genital herpes: review of the evidence. Int Immunopharmacol 2002; 2:443-451.
19. Suzuki H, Wang B, Shivji GM, et al. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J Invest Dermatol 2000; 114:135-141.
20. Urosevic M, Maier T, Benninghoff B, et al. Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo. Arch Dermatol 2003; 139:1325-1332.
21. Ambach A, Bonnekoh B, Nguyen M, et al. Imiquimod, a Toll-like receptor-7 agonist, induces perform in cytotoxic T lymphocytes in vitro. Mol Immunol 2004; 40:1307-1314.
22. Sidbury R, Neuschler N, Neuschler E, et al. Topically applied imiquimod inhibits vascular tumor growth in vivo. J Invest Dermatol 2003; 121:1205-1209.
23. Schon M, Bong AB, Drewniok C, et al. Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst 2003; 95:1138-1149.
24. Meyer T, Nindl I, Schmook T, et al. Induction of apoptosis by Toll-like receptor-7 agonist in tissue cultures. Br J Dermatol 2003; 149 (Suppl 66):9-14.
25. Sullivan TP, Dearaujo T, Vincek V, et al. Evaluation of superficial basal cell carcinomas after treatment with imiquimod 5% cream or vehicle for apoptosis and lymphocyte phenotyping. Dermatol Surg 2003; 29:1181-1186.
26. Beutner KR, Geisse JK. Imiquimod - An immune response modifier for the treatment of genital warts. Today's Therapeutic Trends 1997; 15:165-178.
27. AnonymousImiquimod for genital warts. Med Lett Drugs Ther 1997; 39:118-119.
28. Drug Information for the Health Care ProfessionalMICROMEDEXThompson Healthcare, Greenwood Village, CO 2002.
29. Stockfleth E, Meyer T, Benninghoff B, et al. A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses. Arch Dermatol 2002; 138:1498-1502.
30. Fu W. The Actinic (Solar) Keratosis. Arch Dermatol 2003; 139:66-70.
31. Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol 2000; 42:4-7.
32. Chosidow O, Dummer R. Imiquimod: Mode of action and therapeutic potential. Acta Derm Venereol Suppl (stockh) 2003; Sep; 214:8-11.
33. Lebwohl M, Dinehart S, Whiting D, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol 2004; 50:714-721.
34. Persaud AN, Shamuelova E, Sherer D, et al. Clinical effect of imiquimod 5% cream in the treatment of actinic keratosis. J Am Acad Dermatol 2002; 47:553-556.
35. Salasche SJ, Levine N, Morrison L. Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream: An open-label trial. J Am Acad Dermatol 2002; 47:571-577.
36. Salasche S. Imiquimod 5% cream: a new treatment option for basal cell carcinoma. Int J Dermatol 2002; 41 (Suppl 1)(Suppl 1):6-20.
37. Sterry W, Ruzicka T, Hererra E, et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. Br J Dermatol 2002; 147:1227-1236.
38. Cowen E, Mercurio MG, Gaspari AA. An open case series of patients with basal cell carcinoma treated with topical 5% imiquimod cream. J Am Acad Dermatol 2002; 47:S240-S248.
39. Geisse JK, Rich P, Pandya A, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol 2002; 47:390-398.
40. Beutner KR, Geisse JK, Helman D, et al. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol 1999; 41:1002-1007.
41. Goldgeier M, Fox CA, Zavislan JM, et al. Noninvasive imaging, treatment, and microscopic confirmation of clearance of basal cell carcinoma. Dermatol Surg 2003; 29:205-210.
42. Kagy MK, Amonette R. The use of imiquimod 5% cream for the treatment of superficial basal cell carcinomas in a basal cell nevus syndrome patient. Dermatol Surg 2000; 26:577-578.
43. Marks R, Gebauer K, Shumack S, et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial. J Am Acad Dermatol 2001; 44:807-813.
44. Chen TM, Rosen T, Orengo I. Treatment of a large superficial basal cell carcinoma with 5% imiquimod: a case report and review of the literature. Dermatol Surg 2002; 28:344-346.
45. Geisse J, Caro I, Lindholm J, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 2004; 50:722-733.
46. Slade HB, Kf Jr Jr. Questions from the audience. Eur J Dermatol 1998; 8(Suppl 7):20-21.
47. Shumack S, Robinson J, Kossard S, et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. Arch Dermatol 2002; 138:1165-1171.
48. Weisberg NK, Varghese M. Therapeutic response of a brother and sister with xeroderma pigmentosum to imiquimod 5% cream. Dermatol Surg 2002; 28:518-523.
49. Gutzmer R, Kaspari M, Vogelbruch M, et al. Successful treatment of anogenital Bowen's disease with the immunomodulator imiquimod, and monitoring of therapy by DNA image cytometry. Br J Dermatol 2002; 147:160-165.
50. Danielsen AG, Sand C, Weismann K. Treatment of Bowen's disease of the penis with imiquimod 5% cream. Clin Exp Dermatol 2003; 28 (Suppl 1):7-9.
51. Thai KE, Sinclair RD. Treatment of Bowen's disease of the penis with imiquimod. J Am Acad Dermatol 2002; 46:470-471.
52. Orengo I, Rosen T, Guill CK. Treatment of squamous cell carcinoma in situ of the penis with 5% imiquimod cream: a case report. J Am Acad Dermatol 2002; 47:S225-S228.
53. Schroeder TL, Sengelmann RD. Squamous cell carcinoma in situ of the penis successfully treated with imiquimod 5% cream. J Am Acad Dermatol 2002; 46:545-548.
54. Wu JK, Siller G, Whitehead K. Treatment of Bowen's disease and basal cell carcinoma of the nose with imiquimod 5% cream. Australas J Dermatol 2003; 44:123-125.
55. Mackenzie-Wood A, Kossard S, de Launey J de, et al. Imiquimod 5% cream in the treatment of Bowen's disease. J Am Acad Dermatol 2001; 44:462-470.
56. Smith KJ, Germain M, Skelton H. Squamous cell carcinoma in situ (Bowen's disease) in renal transplant patients treated with 5% imiquimod and 5% 5-fluorouracil therapy. Dermatol Surg 2001; 27:561-564.
57. Ahmed I, Berth-Jones J. Imiquimod: a novel treatment for lentigo maligna. Br J Dermatol 2000; 143:843-845.
58. Chapman MS, Spencer SK, Brennick JB. Histologic resolution of melanoma in situ (lentigo maligna) with 5% imiquimod cream. Arch Dermatol 2003; 139:943-944.
59. Borucki U, Metze D. Topical treatment of lentigo maligna melanoma with imiquimod 5% cream. Dermatology 2003; 207:326-328.
60. Fisher GH, Lang PG. Treatment of melanoma in situ on sun-damaged skin with topical 5% imiquimod cream complicated by the development of invasive disease. Arch Dermatol 2003; 139:945-947.
61. Epstein E. Extensive lentigo maligna clearing with topical imiquimod. Arch Dermatol 2003; 139:944-945.
62. Naylor MF, Crowson N, Kuwahara R, et al. Treatment of lentigo maligna with topical imiquimod. Br J Dermatol 2003; 149 (Suppl 66)(Suppl 66):66-69.
63. Powell AM, Russell-Jones R, Barlow RJ. Topical imiquimod immunotherapy in the management of lentigo maligna. Clin Exp Dermatol 2004; 29:15-21.
64. Fitzpatrick T, Johnson R, Wolff K, et al. Color Atlas and Synopsis of Clinical Dermatology: common and serious diseases McGraw-Hill, New York 1997, p 908.
65. Davis G, Wentworth J, Richard J. Self-administered topical imiquimod treatment of vulvar intraepithelial neoplasia. A report of four cases. J Reprod Med 2000; 45:619-623.
66. Todd RW, Etherington IJ, Luesley DM. The effects of 5% imiquimod cream on high-grade vulval intraepithelial neoplasia. Gynecol Oncol 2002; 85:67-70.
67. Campagne G, Roca M, Martinez A. Successful treatment of a high-grade intraepithelial neoplasia with imiquimod, with vulvar pemphigus as a side effect. Eur J Obstet Gynecol Reprod Biol 2003; 109:224-227.
68. Travis LB, Weinberg JM, Krumholz BA. Successful treatment of vulvar intraepithelial neoplasia with topical imiquimod 5% cream in a lung transplanted patient. Acta Derm Venereol 2002; 82:475-476.
69. Petrow W, Gerdsen R, Uerlich M, et al. Successful topical immunotherapy of bowenoid papulosis with imiquimod. Br J Dermatol 2001; 145:1022-1023.
70. Loo WJ, Holt PJ. Bowenoid papulosis successfully treated with imiquimod. J Eur Acad Dermatol Venereol 2003; 17:363-365.
71. Godfrey JC, Vaughan MC, Williams JV. Successful treatment of bowenoid papulosis in a 9-year-old girl with vertically acquired human immunodeficiency virus. Pediatrics 2003; 112:e73-e76.
72. Steinmann A, Funk JO, Schuler G, et al. Topical imiquimod treatment of a cutaneous melanoma metastasis. J Am Acad Dermatol 2000; 43:555-556.
73. Ugurel S, Wagner A, Pfohler C, et al. Topical imiquimod eradicates skin metastases of malignant melanoma but fails to prevent rapid lymphogenous metastatic spread. Br J Dermatol 2002; 147:621-624.
74. Bong AB, Bonnekoh B, Franke I, et al. Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma. Dermatology 2002; 205:135-138.
75. Wolf IH, Smolle J, Binder B, et al. Topical imiquimod in the treatment of metastatic melanoma to skin. Arch Dermatol 2003; 139:273-276.
76. Suchin KR, Junkins-Hopkins JM, Rook AH. Treatment of stage IA cutaneous T-cell lymphoma with topical application of the immune response modifier imiquimod. Arch Dermatol 2002; 138:1137-1139.
77. Berman B, Poochareon VN, Villa AM. Novel dermatologic uses of the immune response modifier imiquimod 5% cream. Skin Therapy Lett 2002; 7:1-6.
78. Qian Z, Zeitoun NC, Shieh S, et al. Successful treatment of extramammary Paget's disease with imiquimod. J Drugs Dermatol 2003; 2:73-76.
79. Zampogna JC, Flowers FP, Roth WI, et al. Treatment of primary limited cutaneous extramammary Paget's disease with topical imiquimod monotherapy: two case reports. J Am Acad Dermatol 2002; 47:S229-S235.
80. Wang LC, Blanchard A, Judge DE, et al. Successful treatment of recurrent extramammary Paget's disease of the vulva with topical imiquimod 5% cream. J Am Acad Dermatol 2003; 49:769-772.
81. Berman B, Spencer J, Villa A, et al. Successful treatment of extramammary Paget's disease of the scrotum with imiquimod 5% cream. Clin Exp Dermatol 2003; 28(Suppl 1):36-38.
82. Smith KJ, Germain M, Yeager J, et al. Topical 5% imiquimod for the therapy of actinic cheilitis. J Am Acad Dermatol 2002; 47:497-501.
83. Stockfleth E, Rowert J, Arndt R, et al. Detection of human papillomavirus and response to topical 5% imiquimod in a case of stucco keratosis. Br J Dermatol 2000; 143:846-850.
84. Agarwal S, Berth-Jones J. Porokeratosis of Mibelli: successful treatment with 5% imiquimod cream. Br J Dermatol 2002; 146:338-339.
85. Harrison S, Sinclair R. Porokeratosis of Mibelli: successful treat-ment with topical 5% imiquimod cream. Australas J Dermatol 2003; 44:281-283.
86. Hengge UR, Esser S, Schultewolter T, et al. Self-administered topical 5% imiquimod for the treatment of common warts and molluscum contagiosum. Br J Dermatol 2000; 143:1026-10310.
87. Muzio G, Massone C, Rebora A. Treatment of non-genital warts with topical imiquimod 5% cream. Eur J Dermatol 2002; 12:347-349.
88. Schwab RA, Elston DM. Topical imiquimod for recalcitrant facial flat warts. Cutis 2000; 65:160-162.
89. Christensen B, Hengge UR. Recurrent urogenital herpes simplex-successful treatment with imiquimod?. Sex Transm Infect 1999; 75:132-133.
90. Gilbert J, Drehs MM, Weinberg JM. Topical imiquimod for acyclovir-unresponsive herpes simplex virus 2 infection. Arch Dermatol 2001; 137:1015-1017.
91. Bernstein DI, Miller RL, Harrison CJ. Effects of therapy with an immunomodulator (imiquimod, R-837) alone and with acyclovir on genital HSV-2 infection in guinea-pigs when begun after lesion development. Antiviral Res 1993; 20:45-55.
92. Harrison CJ, Miller RL, Bernstein DI. Reduction of recurrent HSV disease using imiquimod alone or combined with a glycoprotein vaccine. Vaccine 2001; 19:1820-1826.
93. Liota E, Smith KJ, Buckley R, et al. Imiquimod therapy for molluscum contagiosum. J Cutan Med Surg 2000; 4:76-82.
94. Bayerl C, Feller G, Goerdt S. Experience in treating molluscum contagiosum in children with imiquimod 5% cream. Br J Dermatol 2003; 149 (Suppl 66):25-29.
95. Skinner RB Jr Jr, Talanin RS. Treatment of molluscum contagiosum with topical 5% imiquimod cream. Pediatr Dermatol 2000; 17:420.
96. Barba AR, Kapoor S, Berman B. An open label safety study of topical imiquimod 5% cream in the treatment of molluscum contagiosum in children. Dermatol Online J 2001; 7:20.
97. Brown CW Jr, O'Donoghue M, Moore J, et al. Recalcitrant molluscum contagiosum in an HIV-afflicted male treated successfully with topical imiquimod. Cutis 2000; 65:363-366.
98. Buckley R, Smith K. Topical imiquimod therapy for chronic giant molluscum contagiosum in a patient with advanced human immunodeficiency virus 1 disease. Arch Dermatol 1999; 135:1167-1169.
99. Strauss RM, Doyle EL, Mohsen AH, et al. Successful treatment of molluscum contagiosum with topical imiquimod in a severely immunocompromised HIV-positive patient. Int J STD AIDS 2001; 12:264-266.
100. Kuwahara RT, Naylor MF, Skinner RB. Treatment of granuloma annulare with topical 5% imiquimod cream. Pediatr Dermatol 2003; 20:90.
101. Martinez MI, Sanchez-Carpintero I, North PE. Infantile hemangioma: clinical resolution with 5% imiquimod cream. Arch Dermatol 2002; 138:881-884.
102. Berman B, Kaufman J. Pilot study of the effect of postoperative imiquimod 5% cream on the recurrence rate of excised keloids. J Am Acad Dermatol 2002; 47:S209-S211.
103. Berman B, Villa A. Imiquimod 5% cream for keloid management. Dermatol Surg 2003; 29:1050-1051.
104. Buates S, Matlashewski G. Treatment of experimental leishmaniasis with the immunomodulators imiquimod and S-28463: efficacy and mode of action. J Infect Dis 1999; 179:1485-1494.
105. Seeberger J, Daoud S, Pammer J. Transient effect of topical treatment of cutaneous leishmaniasis with imiquimod. Int J Dermatol 2003; 42:576-579.
106. Arevalo I, Ward B, Miller R, et al. Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator. Clin Infect Dis 2001; 33:1847-1851.
107. Man J, Dytoc MT. Use of imiquimod cream 5% in the treatment of localized morphea. J Cutan Med Surg 2004; 8:166-169.
108. Namazi MR. Imiquimod: a potential weapon against morphea and fibromatoses. J Drugs Dermatol 2004; 3:362-363.
109. Solis RR, Diven DG, Colome-Grimmer MI, et al. Experimental nonsurgical tattoo removal in a guinea pig model with topical imiquimod and tretinoin. Dermatol Surg 2002; 28:83-86.
110. Stockfleth E, Meyer T, Benninghoff B, et al. Successful treatment of actinic keratosis with imiquimod cream 5%: a report of six cases. Br J Dermatol 2001; 144:1050-1053.
111. Persaud A, Lebwohl M. Imiquimod cream in the treatment of actinic keratoses. J Am Acad Dermatol 2002; 47:S236-S239.
112. Drehs MM, Cook-Bolden F, Tanzi EL, et al. Successful treatment of multiple superficial basal cell carcinomas with topical imiquimod: case report and review of the literature. Dermatol Surg 2002; 28:427-429.